ReviewCureus2024
Efficacy of Anti-Vascular Endothelial Growth Factor (VEGF) Therapy for Age-Related Macular Degeneration.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AAV-based gene therapies for neovascular AMD.Gene therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-vascular endothelial growth factor (VEGF) drugs are used for various diseases with abnormal proliferation of blood vessels. The use of these drugs in wet age-related macular degeneration (AMD) has proven to be highly effective. Various factors contribute to the efficacy of these drugs in different settings. Many studies have proven that these drugs effectively slow disease progress and improve visual outcomes. Factors contributing to the success or failure of the treatment include the genetic makeup of the patient, comorbidities, compliance with the clinic visits and injections, long-term follow-up for the treatment, socioeconomic status, and availability of different drugs. The treatment of choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD) has been revolutionized after the introduction of anti-VEGF therapy. However, there are still some gaps in the literature that require the attention of the researchers. Our literature review has evaluated anti-VEGF use over the years and analyzed the efficiency of drugs in different settings. It showed that all the anti-VEGF drugs depict similar visual results for one to two years. The long-term evaluation of any drug cannot be commented on yet and needs further evidence through different research. These drugs improve visual function and the anatomical results of patients with other eye problems. These drugs' adverse effects are rare but still an important point requiring further research. Clinical outcomes of the drugs must be ascertained through patients' eyes to assess the quality of life improvement appropriately. The cost-effectiveness of the drugs is a substantial debatable topic, as bevacizumab is cost-effective but still requires Food and Drug Administration (FDA) approval.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.